Patent ID: 6903098

Claim:
A method of treating a patient having a disorder characterized by increased activity of poly (ADP-ribose) polymerase (PARP), wherein said disorder to be treated is selected from the group consisting of: neuronal damage, Parkinson's disease, Huntington's disease, damage due to ischemia, epilepsy, damage to the heart following cardiac ischemia, microinfarcts, revascularization of critically narrowed coronary arteries, acute myocardial infarction and damage during and after medical or mechanical lysis thereof, treatment of sepsis or septic shock and diabetes mellitus, said method comprising the step of: administering to a patient in need of such treatment an effective amount of a compound of the formula I in which R 1 is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C 1 -C 6 -alkyl, OH, nitro, CF 3 , CN, NR 11 R 12 , NH—CO—R 13 , O—C 1 -C 4 -alkyl, where R 11 and R 12 are, independently of one another, hydrogen or C 1 -C 4 -alkyl, and R 13 is hydrogen, C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl or phenyl, and A 1 is a straight-chain or branched C 0 -C 6 -alkyl radical and A 2 is NR 2 , NR 2 —C 1 -C 6 -alkyl-, O or S and R 2 is hydrogen or C 1 -C 6 -alkyl and A 3 is an aromatic or heteroaromatic ring with, in each case, 5 or 6 ring atoms and up to 3 heteroatoms selected from N, O, and S, which may also be substituted by R 4 and one or two R 3 , where R 3 can be hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C 1 -C 6 -alkyl, OH, nitro, CF 3 , CN, NR 11 R 12 , SO 2 NR 11 R 12 , SO 2 —C 1 -C 4 -alkyl, S—C 1 -C 4 -alkyl, O-Ph, O—CF 3 , NH—CO—R 13 , O—C 1 -C 4 -alkyl, where R 11 and R 12 are, independently of one another, hydrogen or C 1 -C 4 -alkyl, and R 13 can be hydrogen, C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl or phenyl, R 4 is hydrogen, (X) 0,1 —C 1 -C 4 -alkyl-NR 41 R 42 , where X═O, S and NR 43 or R 41 and R 42 can be independently of one another, hydrogen, C 1 -C 6 -alkyl, phenyl-C 1 -C 4 -alkyl or a 3 to 7-membered cyclic amine and R 43 can be hydrogen or C 1 -C 4 -alkyl, and its tautomeric forms, and its prodrugs.